AnaptysBio Inc. (Nasdaq: ANAB) reported positive proof-of-concept data from an ongoing Phase 2a clinical trial of ANB020 to treat moderate to severe atopic dermatitis. Shares of the biotechnology firm more than doubled by leaping $35.41 to close at $70.41.
AnaptysBio reports positive data
October 10, 2017 at 17:20 PM EDT